Resmetirom, a novel liver-targeted selective thyroid hormone receptor-beta (THR-β) agonist, has shown positive effects for the treatment of dyslipidemia and other metabolic disorders, including non-alcoholic steatohepatitis (NASH) [1]. The relevance of this drug lies in its ability to decrease atherogenic lipid levels, which may reduce the risk of cardiovascular disease [2]. Clinical trials have found that resmetirom induces dose-dependent reductions in atherogenic lipids such as triglycerides, low-density lipoprotein (LDL) cholesterol, non-high-density lipoprotein (non-HDL) cholesterol, apolipoprotein B (apoB), apolipoprotein CIII (apoCIII), and lipoprotein (a) [lp(a)] [3].
